Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

MLA

Ulf Petrausch, et al. “Serological SARS‐CoV‐2 Antibody Response, Potential Predictive Markers and Safety of BNT162b2 MRNA COVID‐19 Vaccine in Haematological and Oncological Patients.” British Journal of Haematology, vol. 195, Aug. 2021, pp. 523–31. EBSCOhost, https://doi.org/10.1111/bjh.17743.

APA

Ulf Petrausch, Michele Atzl, Hanno Ulmer, Thomas Winder, Andreas Volgger, Magdalena Benda, Peter Fraunberger, Theresia Lang, Minh Huynh, Bernd L. Hartmann, Claudia Grabher, Beatrix Mutschlechner, Klaus Gasser, Luciano Severgnini, & Patrick Reimann. (2021). Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients. British Journal of Haematology, 195, 523–531. https://doi.org/10.1111/bjh.17743

Chicago

Ulf Petrausch, Michele Atzl, Hanno Ulmer, Thomas Winder, Andreas Volgger, Magdalena Benda, Peter Fraunberger, et al. 2021. “Serological SARS‐CoV‐2 Antibody Response, Potential Predictive Markers and Safety of BNT162b2 MRNA COVID‐19 Vaccine in Haematological and Oncological Patients.” British Journal of Haematology 195 (August): 523–31. doi:10.1111/bjh.17743.